In hematologic cancer, AhR activation using FICZ not only improves the ability of NK cells to produce IFN-γ and cytolytic activity, but also enhances the ability of NK cells to inhibit cancer growth in an AhR-dependent manner (60). This evidence concerns the gene AHR and hematopoietic and lymphoid cell neoplasm.